热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　大成生化科技（00809）发布截至2024年12月31日止年度全年业绩，持续经营业务收益20.01亿港元，同比增加45.65%；股东应占溢利7.7亿港元，同比减少81.78%；每股基本盈利8.6港仙。

　　公告称，于本年度，集团继续进行组织架构调整及精简运营业务。集团已完成出售事项，及后已出售集团的各公司不再为公司附属公司及其各自的财务业绩、资产及负债已终止合并入集团综合财务报表。因此，集团于本年度就出售事项确认一次性收益约19.62亿港元。另一方面，集团致力最大限度地提高氨基酸业务生产设施的产能，并推出一系列高增值氨基酸产品，以扩大2024年的销售。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.